OxiracetamvsTheacrine

Oxiracetam enhances glutamatergic neurotransmission through positive allosteric modulation of AMPA receptors, increasing the amplitude and duration of excitatory postsynaptic potentials. It increases the release of excitatory neurotransmitters glutamate and D-aspartic acid from hippocampal presynaptic terminals, acting as a glutamate analog. Oxiracetam stimulates protein kinase C (PKC) isoforms, particularly PKC-α and PKC-γ, which phosphorylate substrates involved in memory consolidation, long-term potentiation (LTP), and synaptic plasticity. PKC activation enhances NMDA receptor function and AMPA receptor trafficking to the synapse. Its mild stimulatory effect derives from cholinergic system enhancement via increased acetylcholine release and nicotinic α7 receptor potentiation in the cortex.

Theacrine activates dopamine receptors (D1 and D2 families) — likely as an indirect agonist via dopamine release or reuptake inhibition — and inhibits adenosine A1 and A2A receptors as an antagonist, similar to caffeine. Unlike caffeine, theacrine does not cause upregulation of adenosine receptors (A1R, A2AR) with chronic use, which is why tolerance does not develop; the structural difference (1,3,7-trimethyluric acid vs 1,3,7-trimethylxanthine) may alter receptor binding kinetics or downstream signaling. It modulates the adenosinergic and dopaminergic systems in a manner that maintains sensitivity over time — possibly through different metabolism (theacrine has a 16-20 hour half-life) or receptor interaction profiles. Theacrine provides anti-inflammatory effects through inhibition of NF-kB (reducing IKK activity and p65 nuclear translocation) and may have additional effects on phosphodiesterase inhibition, increasing cAMP.